Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 5, 2011, Pages 1394-1398

  Tallant, Matthew D ^a   Duan, Maosheng ^a   Freeman, George A ^a   Ferris, Robert G ^a   Edelstein, Mark P ^a   Kazmierski, Wieslaw M ^a   Wheelan, Pat J ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Benzimidazole; CCR5; Diaminobutane; HIV 1; Tropane

Indexed keywords

2 METHYL 2 PHENYL 1,4 DIAMINOBUTANE; 2 PHENYL 1,4 DIAMINOBUTANE; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL EVALUATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; RAT; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; INHIBITORY CONCENTRATION 50; PUTRESCINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CCR5;

HUMAN IMMUNODEFICIENCY VIRUS 1; RATTUS;

EID: 79951724365     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.030     Document Type: Article

References (12)

1. T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A.K. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore, and W.A. Paxton Nature 381 1996 667
2. W.M. Kazmierski, K.S. Gudmundsson, and S.C. Piscitelli Annu. Rep. Med. Chem. 42 2007 301
3. A. Wood, and D. Armour Prog. Med. Chem. 43 2005 239
4. W.M. Kazmierski, C. Aquino, B. Chauder, F. Deanda, R. Ferris, D. Jones-Hertog, T. Kenakin, C. Koble, C. Watson, P. Wheelan, H. Yang, and M. Youngman J. Med. Chem. 51 2008 6538
5. P. Finke, B. Oates, S. Mills, M. MacCoss, L. Malkowitz, M. Springer, S. Gould, J. DeMartino, A. Carella, G. Carver, K. Holmes, R. Danzeisen, D. Hazuda, J. Kessler, J. Lineberger, M. Miller, W. Schleif, and E. Emini Bioorg. Med. Chem. Lett. 11 2001 2475
6. Caldwell, C. G.; Chen, P.; Finke, P. E.; Shankaran, K.; Meurer, L. C.; Oates, B.; Dorn, C. P., Jr.; MacCoss, M.; Mills, S. G.; DeMartino, J. A.; Gould, S. L.; Malkowitz, L.; Siciliano, S. J.; Springer, M. S.; Braun, J.; Chen, Q.; Hajdu, R.; Kwei, G.; Carella, A.; Carver, G.; Danzeisen, R.; Hazuda, D. J.; Holmes, K.; Kessler, J.; Lineberger, J.; Miller, M.; Emini, E. A.; Schleif, W. A. Abstract of Papers, 220th ACS National Meeting, Washington, DC, Aug 24-29, 2000; American Chemical Society: Washington, DC, 2000; MEDI 120.
7. WO 2004/054974.
8. J. Bagley, and T. Riley J. Heterocycl. Chem. 19 1982 485
9. WO 2005/101989. See also Price, D. Synlett 2005, 1133.
10. G. Woods, T. Heying, L. Schwartzman, S. Grenell, W. Gasser, E. Rowe, and N. Bolgiano J. Org. Chem. 19 1954 1290
11. V. Muniz-Medina, S. Jones, J. Maglich, C. Galardi, R. Hollingsworth, W. Kazmierski, R. Ferris, M. Edelstein, K. Chiswell, and Y. Kenakin Mol. Pharmacol. 75 2009 490
12. Maraviroc bioavailability was reported to be 6% at 10 mg/kg PO dose (Drug Metab. Dispos. 2005, 587-595). However, under conditions employed to evaluate PK of analogues in Table 5, MVC plasma concentration after oral dosing was undetectable.